Global Myasthenia Gravis Drugs Market 2017-2021

重症筋無力症治療薬の世界市場2017-2021:抗コリンエステラーゼ薬、免疫抑制剤、免疫グロブリン静注療法(IVIg)

◆タイトル:Global Myasthenia Gravis Drugs Market 2017-2021
◆商品コード:IRTNTR11520
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年1月12日
◆ページ数:73
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥392,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥504,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥560,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、重症筋無力症治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、重症筋無力症治療薬の世界市場規模及び予測、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Myasthenia Gravis Drugs
Currently, the myasthenia gravis drugs market stands at a small size due to limited availability of approved therapies for the complete remission of the disease. However, the anticipated approval of novel drugs such as monoclonal antibodies should help market witness strong growth during the forecast period. For instance, Alexion Pharmaceuticals is currently developing a monoclonal antibody, Soliris, for the treatment of myasthenia gravis. Once launched around end 2017 or beginning of 2018, this drug is expected to be the blockbuster drug for the market.

Technavio’s analysts forecast the global myasthenia gravis drugs market to grow at a CAGR of 13.16% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global myasthenia gravis drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of myasthenia gravis drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Myasthenia Gravis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Flamel Technologies
• F. Hoffmann-La Roche
• Grifols
• Pfizer
• Shire
• Valeant Pharmaceuticals

[Other prominent vendors]
• Alexion Pharmaceuticals
• Catalyst Pharmaceuticals
• CSL
• Curavac
• Cytokinetics
• Galencia
• GlaxoSmithKline
• Lupin Pharmaceuticals
• Mitsubishi Tanabe Pharma
• Novartis

[Market driver]
• Approval of novel monoclonal antibodies
• For a full, detailed list, view our report

[Market challenge]
• Limited availability of approved drugs
• For a full, detailed list, view our report

[Market trend]
• Emergence of new entrants
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Highlights

PART 05: Pipeline analysis

PART 06: Market landscape
• Global myasthenia gravis drugs market
• Five forces analysis

PART 07: Market segmentation by therapy area
• Anticholinesterases
• Immunosuppressants
• IVIg

PART 08: Geographical segmentation
• Myasthenia gravis drugs market in Americas
• Myasthenia gravis drugs market in EMEA
• Myasthenia gravis drugs market in APAC

PART 09: Market drivers
• Approval of novel monoclonal antibodies
• High unmet medical need
• Growing research activities for the better understanding and diagnosis of myasthenia gravis

PART 10: Impact of drivers

PART 11: Market challenges
• Presence of substitutes
• Limited availability of approved drugs
• Lack of long-term commitment

PART 12: Impact of drivers and challenges

PART 13: Market trends
• Emergence of new entrants
• Growing strategic acquisitions
• Potential treatment options

PART 14: Vendor landscape
• Competitive scenario

PART 15: Key vendor analysis
• Flamel Technologies
• F. Hoffmann-La Roche
• Grifols
• Pfizer
• Shire
• Valeant Pharmaceuticals
• Other prominent vendors

PART 16: Appendix
• List of abbreviations

PART 17: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key customer segments of global myasthenia gravis drugs market
Exhibit 03: Factors affecting the adoption rates of myasthenia gravis drugs market
Exhibit 04: Key pipeline candidates
Exhibit 05: Global myasthenia gravis drugs market snapshot
Exhibit 06: Analysis of global myasthenia gravis drugs market
Exhibit 07: Global myasthenia gravis drugs market 2016-2021 ($ millions)
Exhibit 08: Opportunity analysis of global myasthenia gravis drugs market
Exhibit 09: Opportunity analysis in developed and emerging markets
Exhibit 10: Five forces analysis
Exhibit 11: Segmentation of global myasthenia gravis drugs market by therapy
Exhibit 12: Segmentation of global myasthenia gravis drugs market based on geography 2016 and 2021
Exhibit 13: Global myasthenia gravis drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 14: Market scenario in Americas
Exhibit 15: Myasthenia gravis drugs market in Americas 2016-2021 ($ millions)
Exhibit 16: Market scenario in EMEA
Exhibit 17: Myasthenia gravis drugs market in EMEA 2016-2021 ($ millions)
Exhibit 18: Market scenario in APAC
Exhibit 19: Myasthenia gravis drugs market in APAC 2016-2021 ($ millions)
Exhibit 20: Key drivers and challenges in APAC
Exhibit 21: Key pipeline monoclonal antibodies
Exhibit 22: Incidence data for myasthenia gravis (annually)
Exhibit 23: Impact of drivers
Exhibit 24: Forcefield analysis of drivers and challenges
Exhibit 25: Impact of drivers and challenges
Exhibit 26: Key entrants in myasthenia gravis drugs market
Exhibit 27: Key acquisitions and their impact
Exhibit 28: Competitive structure analysis of global myasthenia gravis drugs market 2015
Exhibit 29: Competitive analysis of global myasthenia gravis drugs market
Exhibit 30: Market penetration of various myasthenia gravis manufacturers 2015
Exhibit 31: Flamel Technologies: Key highlights
Exhibit 32: Flamel Technologies: Strength assessment
Exhibit 33: Flamel Technologies: Strategy assessment
Exhibit 34: Flamel Technologies: Opportunity assessment
Exhibit 35: F. Hoffmann-La Roche: Strength assessment
Exhibit 36: F. Hoffmann-La Roche: Strategy assessment
Exhibit 37: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 38: F. Hoffmann-La Roche: Year-over-year (YoY) growth and revenue of MabThera/Rituxan 2013-2015 ($ billions)
Exhibit 39: F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015
Exhibit 40: F. Hoffmann-La Roche: YoY growth and revenue of CellCept 2013-2015 ($ millions)
Exhibit 41: Grifols: Key highlights
Exhibit 42: Grifols: Strength assessment
Exhibit 43: Grifols: Strategy assessment
Exhibit 44: Grifols: Opportunity assessment
Exhibit 45: Pfizer: Strength assessment
Exhibit 46: Pfizer: Strategy assessment
Exhibit 47: Pfizer: Opportunity assessment
Exhibit 48: Pfizer: YoY and growth rate of Medrol 2013-2015 ($ millions)
Exhibit 49: Shire: Key highlights
Exhibit 50: Shire: Strength assessment
Exhibit 51: Shire: Strategy assessment
Exhibit 52: Shire: Opportunity assessment
Exhibit 53: Valeant Pharmaceuticals: Strength assessment
Exhibit 54: Valeant Pharmaceuticals: Strategy assessment
Exhibit 55: Valeant Pharmaceuticals: Opportunity assessment



【掲載企業】

Flamel Technologies, F. Hoffmann-La Roche, Grifols, Pfizer, Shire, Valeant Pharmaceuticals, Alexion Pharmaceuticals, Catalyst Pharmaceuticals, CSL, Curavac, Cytokinetics, Galencia, GlaxoSmithKline, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma, Novartis.

【資料のキーワード】

重症筋無力症治療薬、重症筋無力症治療薬治療分野、抗コリンエステラーゼ薬、免疫抑制剤、免疫グロブリン静注療法(IVIg)

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[重症筋無力症治療薬の世界市場2017-2021:抗コリンエステラーゼ薬、免疫抑制剤、免疫グロブリン静注療法(IVIg)] (Global Myasthenia Gravis Drugs Market 2017-2021 / IRTNTR11520)販売に関する免責事項
[重症筋無力症治療薬の世界市場2017-2021:抗コリンエステラーゼ薬、免疫抑制剤、免疫グロブリン静注療法(IVIg)] (Global Myasthenia Gravis Drugs Market 2017-2021 / IRTNTR11520)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆